Q4 2024 |
1,402 |
$8.4B |
+$2.12B |
-$403M |
+$1.72B |
ACIO, DRSK, AAPL, MSFT, NVDA
|
13F-HR |
2/14/2025, 04:22 PM |
Q3 2024 |
1,231 |
$6.53B |
+$1.22B |
-$167M |
+$1.05B |
ACIO, DRSK, AAPL, OSCV, MSFT
|
13F-HR |
11/5/2024, 04:33 PM |
Q2 2024 |
1,159 |
$5.23B |
+$873M |
-$253M |
+$620M |
ACIO, DRSK, MSFT, OSCV, AAPL
|
13F-HR |
7/31/2024, 04:55 PM |
Q1 2024 |
1,157 |
$4.66B |
+$1.18B |
-$139M |
+$1.04B |
ACIO, DRSK, OSCV, JUCY, MSFT
|
13F-HR |
5/15/2024, 04:22 PM |
Q4 2023 |
915 |
$3.66B |
+$203M |
-$548M |
-$345M |
ACIO, DRSK, OSCV, AAPL, MSFT
|
13F-HR |
2/13/2024, 02:58 PM |
Q3 2023 |
935 |
$3.67B |
+$747M |
-$1.11B |
-$366M |
ACIO, DRSK, TLT, OSCV, AAPL
|
13F-HR |
11/8/2023, 02:33 PM |
Q2 2023 |
792 |
$4.17B |
+$973M |
-$373M |
+$599M |
ACIO, DRSK, TLT, OSCV, SO
|
13F-HR |
8/11/2023, 10:13 AM |
Q1 2023 |
786 |
$3.72B |
+$683M |
-$257M |
+$426M |
DRSK, ACIO, DDOG, ADME, OSCV
|
13F-HR |
5/9/2023, 03:19 PM |
Q4 2022 |
793 |
$3.26B |
+$570M |
-$687M |
-$117M |
DRSK, ACIO, DDOG, IBDS, ADME
|
13F-HR |
2/13/2023, 03:13 PM |
Q3 2022 |
749 |
$4.15B |
+$1.37B |
-$229M |
+$1.14B |
LQD, TLT, DRSK, ACIO, ADME
|
13F-HR |
11/2/2022, 11:49 AM |
Q2 2022 |
644 |
$3.84B |
+$1.69B |
-$241M |
+$1.45B |
DRSK, EFA, LOW, ACIO, IBDS
|
13F-HR |
7/29/2022, 02:54 PM |
Q1 2022 |
659 |
$4B |
+$1.28B |
-$57.7M |
+$1.22B |
DRSK, FIS, IBDQ, IBDO, IBDR
|
13F-HR |
5/4/2022, 12:36 PM |
Q4 2021 |
543 |
$3.33B |
+$744M |
-$58.9M |
+$685M |
DRSK, IBDO, IBDQ, IBDP, ACIO
|
13F-HR |
2/2/2022, 02:03 PM |
Q3 2021 |
515 |
$2.53B |
+$536M |
-$176M |
+$360M |
DRSK, IBDO, IBDN, IBDP, ACIO
|
13F-HR |
10/27/2021, 04:33 PM |
Q2 2021 |
539 |
$2.2B |
+$247M |
-$46.3M |
+$201M |
DRSK, IBDO, ADME, ACIO, IBDN
|
13F-HR |
7/27/2021, 01:18 PM |
Q1 2021 |
487 |
$1.92B |
+$284M |
-$106M |
+$179M |
DRSK, IBDO, ACIO, ADME, IBDN
|
13F-HR |
5/6/2021, 02:38 PM |
Q4 2020 |
452 |
$2.17B |
+$613M |
-$57.4M |
+$556M |
DRSK, ADME, ACIO, IBDO, IBDN
|
13F-HR |
2/10/2021, 02:12 PM |
Q3 2020 |
454 |
$1.88B |
+$603M |
-$180M |
+$423M |
DRSK, ADME, ACIO, QQQ, LQD
|
13F-HR |
10/16/2020, 05:40 PM |
Q2 2020 |
401 |
$1.59B |
+$555M |
-$79.3M |
+$476M |
DRSK, ACIO, ADME, SPY, IBDO
|
13F-HR |
7/22/2020, 10:21 AM |
Q1 2020 |
393 |
$1.16B |
+$370M |
-$144M |
+$226M |
DRSK, ACIO, ADME, BSCK, QQQ
|
13F-HR |
5/7/2020, 10:40 AM |
Q4 2019 |
490 |
$1.41B |
+$542M |
-$702M |
-$160M |
DRSK, QQQ, ACIO, ADME, SPY
|
13F-HR |
2/10/2020, 12:53 PM |
Q3 2019 |
466 |
$1.79B |
+$1.19B |
-$80.1M |
+$1.11B |
SPY, DRSK, ACIO, FTVA, ADME
|
Restatement |
11/14/2019, 04:15 PM |
Q2 2019 |
325 |
$709M |
+$170M |
-$24.2M |
+$145M |
DRSK, FTVA, ADME, OSCV, SPDW
|
13F-HR |
8/12/2019, 05:55 PM |
Q1 2019 |
302 |
$583M |
+$307M |
-$14.8M |
+$292M |
DRSK, FTVA, ADME, OSCV, IBDR
|
13F-HR |
5/15/2019, 04:18 PM |
Q4 2018 |
171 |
$378M |
|
|
|
DRSK, IEF, FTVA, SHY, SPLG
|
13F-HR |
2/12/2019, 02:07 PM |